Aclaris Therapeutics, Inc. (ACRS) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Aclaris Therapeutics reported revenue of $7.8M, down 58.2% from $18.7M the year before. Net income was -$64.9M (a -829.6% net margin), or -$0.53 per diluted share. Gross margin was 73.3% and operating margin was -975.9%. Operating activities generated -$47.1M of cash, leaving -$47.2M of free cash flow. At fiscal year end, Aclaris Therapeutics held $160.5M in total assets against $57.4M in total liabilities, including $20.0M of cash and equivalents.
Open the full interactive Aclaris Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Aclaris Therapeutics Key Stats
| Share Price | $3.47 |
|---|---|
| Market Cap | $495.3M |
| Revenue YoY Growth | -58.2% |
| 52-Week Range | $1.81 – $6.53 |
| Shares Outstanding | 142.7 million (basic, 2026 Q2) |
Aclaris Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $6.5M | $6.8M | $29.8M | $31.2M | $18.7M | $7.8M |
| Cost of Goods Sold | $57.4M | $96.5M | $119.6M | $128.6M | $160.7M | $84.2M |
| Gross Profit | $1.3M | $2.0M | $25.7M | $27.8M | $15.9M | $5.7M |
| Operating Income | -$50.9M | -$89.7M | -$89.9M | -$97.4M | -$141.9M | -$76.4M |
| Pre-Tax Income | -$51.2M | -$90.9M | -$86.9M | -$88.8M | -$132.1M | -$64.9M |
| Income Tax | -$182,000 | — | — | -$367,000 | — | — |
| Net Income | -$51.0M | -$90.9M | -$86.9M | -$88.5M | -$132.1M | -$64.9M |
| Diluted EPS | -$1.20 | -$1.60 | -$1.33 | -$1.27 | -$1.71 | -$0.53 |
Aclaris Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $3.3M | $1.3M | $2.0M | $1.6M |
| Net Income | -$14.6M | -$19.8M | -$19.8M | -$21.5M |
| Diluted EPS | -$0.12 | -$0.16 | -$0.15 | -$0.15 |
Aclaris Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $22.1M | $27.3M | $45.3M | $39.9M | $24.6M | $20.0M |
| Current Assets | $57.5M | $205.0M | $231.6M | $128.9M | $126.0M | $96.3M |
| Total Assets | $70.8M | $251.2M | $254.6M | $197.4M | $220.3M | $160.5M |
| Current Liabilities | $14.9M | $22.9M | $21.9M | $31.0M | $31.6M | $28.6M |
| Total Long-Term Debt | $10.7M | — | — | — | — | — |
| Total Liabilities | $33.1M | $53.9M | $57.0M | $40.2M | $64.8M | $57.4M |
| Shareholders' Equity | $37.6M | $197.3M | $197.6M | $157.2M | $155.6M | $103.1M |
Aclaris Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$38.6M | -$52.1M | -$67.6M | -$78.3M | -$20.1M | -$47.1M |
| Cash From Investing | $6.4M | -$167.6M | $12.6M | $46.2M | -$69.8M | $48.4M |
| Cash From Financing | $18.4M | $225.1M | $72.9M | $26.7M | $74.5M | -$5.9M |
| Free Cash Flow | -$39.1M | -$52.4M | -$68.2M | -$79.6M | -$20.2M | -$47.2M |
Figures from Aclaris Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Aclaris Therapeutics financials page for every line item.
Aclaris Therapeutics Company Profile
| Ticker | ACRS |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Wayne, Pennsylvania |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001557746 |
Frequently Asked Questions
What was Aclaris Therapeutics' revenue in fiscal 2025?
Aclaris Therapeutics (ACRS) reported revenue of $7.8M for fiscal 2025.
What is Aclaris Therapeutics' annual revenue history?
Aclaris Therapeutics' annual revenue by fiscal year: 2020: $6.5M; 2021: $6.8M; 2022: $29.8M; 2023: $31.2M; 2024: $18.7M; 2025: $7.8M.
What was Aclaris Therapeutics' net income in fiscal 2025?
Aclaris Therapeutics reported net income of -$64.9M for fiscal 2025.
What was Aclaris Therapeutics' earnings per share (EPS) in fiscal 2025?
Aclaris Therapeutics' diluted EPS was -$0.53 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Aclaris Therapeutics generate in fiscal 2025?
Aclaris Therapeutics generated -$47.2M of free cash flow in fiscal 2025.
What was Aclaris Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Aclaris Therapeutics reported revenue of $1.6M.
How many shares of Aclaris Therapeutics are outstanding?
Aclaris Therapeutics reported a weighted average of 142.7 million basic shares outstanding in 2026 Q2.
What is Aclaris Therapeutics' market cap?
Based on its latest closing price, Aclaris Therapeutics (ACRS) has a market capitalization of about $495.3M.
When does Aclaris Therapeutics' fiscal year end?
Aclaris Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Aclaris Therapeutics headquartered?
Aclaris Therapeutics lists its business address in Wayne, Pennsylvania in its SEC filings.